cfDNA screening performance: accounting for and reducing test failures.

about

cfDNA screening performance: accounting for and reducing test failures.

Item

http://www.wikidata.org/entity/Q48249414

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

cfDNA screening performance: accounting for and reducing test failures.

@en

cfDNA screening performance: accounting for and reducing test failures.

@nl

type

Item

label

cfDNA screening performance: accounting for and reducing test failures.

@en

cfDNA screening performance: accounting for and reducing test failures.

@nl

prefLabel

cfDNA screening performance: accounting for and reducing test failures.

@en

cfDNA screening performance: accounting for and reducing test failures.

@nl

P1476

cfDNA screening performance: accounting for and reducing test failures.

@en

P2093

H Cuckle

http://www.w3.org/2001/XMLSchema#string

P2860

Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening.

Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort

Non-invasive prenatal chromosomal aneuploidy testing--clinical experience: 100,000 clinical samples.

Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing.

Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases.

Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies.

Non-invasive prenatal testing for aneuploidy: current status and future prospects.

Cell-free DNA screening for fetal aneuploidy as a clinical service.

The IONA® Test: Development of an Automated Cell-Free DNA-Based Screening Test for Fetal Trisomies 13, 18, and 21 That Employs the Ion Proton Semiconductor Sequencing Platform.

Obesity and cell-free DNA "no calls": is there an optimal gestational age at time of sampling?

P304

689-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/UOG.17492

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

H Cuckle

P577

2017-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28429561

http://www.w3.org/2001/XMLSchema#string